IS2457B - Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum - Google Patents

Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum

Info

Publication number
IS2457B
IS2457B IS6806A IS6806A IS2457B IS 2457 B IS2457 B IS 2457B IS 6806 A IS6806 A IS 6806A IS 6806 A IS6806 A IS 6806A IS 2457 B IS2457 B IS 2457B
Authority
IS
Iceland
Prior art keywords
pentamidine
chlorpromazine
drugs
compositions
treatment
Prior art date
Application number
IS6806A
Other languages
English (en)
Other versions
IS6806A (is
Inventor
Borisy Alexis
Keith Curtis
A. Foley Michael
R. Stockwell Brent
Original Assignee
Combinatorx, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx, Incorporated filed Critical Combinatorx, Incorporated
Publication of IS6806A publication Critical patent/IS6806A/is
Publication of IS2457B publication Critical patent/IS2457B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IS6806A 2000-11-06 2003-05-05 Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum IS2457B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/706,929 US6569853B1 (en) 2000-11-06 2000-11-06 Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
PCT/US2001/047959 WO2002058684A2 (en) 2000-11-06 2001-10-30 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders

Publications (2)

Publication Number Publication Date
IS6806A IS6806A (is) 2003-05-05
IS2457B true IS2457B (is) 2008-11-15

Family

ID=24839666

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6806A IS2457B (is) 2000-11-06 2003-05-05 Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum

Country Status (29)

Country Link
US (4) US6569853B1 (is)
EP (1) EP1339399B1 (is)
JP (1) JP2004517915A (is)
KR (1) KR100720205B1 (is)
CN (1) CN1484525A (is)
AR (1) AR035500A1 (is)
AT (1) ATE318590T1 (is)
AU (1) AU2002246636B8 (is)
BG (1) BG107831A (is)
BR (1) BR0115166A (is)
CA (1) CA2436799C (is)
CY (1) CY1105501T1 (is)
DE (1) DE60117615T2 (is)
DK (1) DK1339399T3 (is)
EE (1) EE200300212A (is)
ES (1) ES2258566T3 (is)
HR (1) HRP20030460A2 (is)
HU (1) HUP0400529A3 (is)
IL (1) IL155795A0 (is)
IS (1) IS2457B (is)
MX (1) MXPA03003960A (is)
NO (1) NO20032036L (is)
NZ (1) NZ525773A (is)
PL (1) PL362690A1 (is)
PT (1) PT1339399E (is)
RU (1) RU2286769C2 (is)
SK (1) SK5452003A3 (is)
TW (1) TWI259077B (is)
WO (1) WO2002058684A2 (is)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1231910T3 (da) * 1999-11-16 2009-08-31 Oncozyme Pharma Inc Pentamidin til behandling af cancer
DE10015818A1 (de) * 2000-03-30 2001-10-18 Infineon Technologies Ag Biosensor und Verfahren zum Ermitteln makromolekularer Biopolymere mit einem Biosensor
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US6992082B2 (en) * 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
CA2451845A1 (en) * 2001-05-31 2002-12-05 The Cleveland Clinic Foundation Ptpase inhibitors and method of using same
FR2825279B1 (fr) * 2001-06-01 2005-04-08 Molecular Engines Lab Medicament utile dans le traitement du cancer
US20040010045A1 (en) * 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US20050215629A1 (en) * 2001-09-07 2005-09-29 Taolin Yi PTPase inhibitors and methods of using the same
EP1572070A4 (en) 2001-09-07 2009-11-04 Cleveland Clinic Foundation THERAPEUTIC COMPOSITIONS AND METHOD FOR MODULATING PROTEIN TYROSINE PHOSPHATASES
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
AU2004201240B2 (en) * 2001-09-27 2008-08-07 Bar Ilan University Conjugated Psychotropic Drugs and Uses Thereof
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
AU2003241346A1 (en) * 2002-05-01 2003-11-17 The Cleveland Clinic Foundation Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
JP2005536509A (ja) * 2002-07-11 2005-12-02 コンビナトアールエックス インコーポレーティッド 新生物の治療のための薬物の組み合わせ
ES2343411T3 (es) * 2003-03-26 2010-07-30 Synergy Biosystems Ltd. Procedimientos para identificar agentes biologicamente activos y combinaciones sinergicas.
WO2004111199A2 (en) * 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
AU2004273910A1 (en) * 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
TW200526777A (en) * 2003-11-12 2005-08-16 Combinatorx Inc Combinations for the treatment of proliferative diseases
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
WO2005046694A1 (en) * 2003-11-13 2005-05-26 Københavns Universitet Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance
US7510710B2 (en) * 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
US7262223B2 (en) 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
CA2561513C (en) 2004-03-29 2019-02-26 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
EP1744781B1 (en) 2004-04-30 2012-07-04 BKG Pharma ApS Treatment of infectious diseases
WO2005117847A2 (en) * 2004-06-02 2005-12-15 Combinatorx, Incorporated Methods and compounds for the treatment of neoplasms
WO2006078774A2 (en) * 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Regulation of autophagy and cell survival
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
EP1877060A2 (en) * 2005-04-28 2008-01-16 The Regents of the University of Colorado Therapeutic bifunctional compounds
JP2008543734A (ja) * 2005-05-02 2008-12-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 脂肪酸代謝および解糖の阻害を提供する化合物の組み合わせ、または二官能性化合物を用いるヒトの炎症性および増殖性疾患を処置するためのシステムおよび方法
US9233094B2 (en) 2005-05-04 2016-01-12 Medigene Ag Method of administering a cationic liposomal preparation
DE102005024017A1 (de) * 2005-05-25 2006-11-30 Merck Patent Gmbh Chinazolinone
ES2400772T3 (es) * 2005-06-07 2013-04-12 Ramot At Tel Aviv University Ltd. Sales novedosas de fármacos psicotrópicos conjugados y procedimientos para la preparación de las mismas
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US20070202079A1 (en) * 2006-01-11 2007-08-30 Taolin Yi Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
AU2007228984B2 (en) 2006-03-22 2012-05-03 Syncore Biotechnology Co., Ltd Treatment of triple receptor negative breast cancer
WO2007149381A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
US20080226596A1 (en) * 2006-06-19 2008-09-18 Taolin Yi Therapeutic compositions and methods useful in treating hepatitis
ES2393933T3 (es) * 2006-07-17 2013-01-02 Ramot, At Tel Aviv University Ltd. Conjugados que comprenden un fármaco psicotrópico o un agonista GABA y un ácido orgánico y su uso para el tratamiento del dolor y otros transtornos del SNC
WO2008080398A1 (en) 2007-01-05 2008-07-10 Bkg Pharma Aps Anti - infective agents such as phenothiazine and thioxanthene derivates to treat infectious diseases
DK2124857T3 (en) * 2007-01-09 2017-07-03 Fovea Pharmaceuticals DEVICE FOR INTRAOCULAR INJECTION
DE102007013854A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydrochinoline
DE102007013856A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydropyrrolochinoline
DE102007013855A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
US20110009351A1 (en) * 2007-05-09 2011-01-13 Traffick Therepeutics Inc. Screening assay to identify correctors of protein trafficking defects
CN101138558B (zh) * 2007-09-13 2010-08-25 汕头大学医学院 喷他脒及死亡结构域受体配体联合应用
EP2194981B1 (en) * 2007-10-05 2011-11-23 Université de Mons-Hainaut Bisbenzimidazoles as antimalarial agents
US8207369B2 (en) 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
EP2318008A1 (en) * 2008-07-18 2011-05-11 Immune Control, Inc. Binding and inhibiting 5-ht4 receptor
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) * 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
EP2424516A4 (en) * 2009-05-01 2014-04-02 Oncozyme Pharma Inc PENTAMIDINE COMBINATIONS FOR THE TREATMENT OF CANCER
CN102439453A (zh) 2009-05-20 2012-05-02 日内瓦大学 癌症起始细胞的线粒体活性抑制剂及其用途
WO2011035225A1 (en) * 2009-09-21 2011-03-24 President And Fellows Of Harvard College Synergistic combination therapy
EP2509603A1 (en) * 2009-12-09 2012-10-17 Biolinerx Ltd. Methods of improving cognitive functions
US20130165417A1 (en) * 2010-04-23 2013-06-27 University Of Florida Research Foundation Methods and compositions for treating ace2-related disorders
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
PT2550963T (pt) * 2011-07-25 2017-01-19 Dritte Patentportfolio Beteili Ésteres de ácido carboxílico de amidoxima de pentamidina como pró-drogas, e a utilização dos mesmos como fármaco
TR201903280T4 (tr) * 2011-08-02 2019-04-22 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Malt1 proteazının fenotiazin türevleri ile selektif inhibisyonu.
WO2014086478A1 (en) * 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
CN104968340A (zh) * 2012-12-21 2015-10-07 沃利克斯制药股份有限公司 治疗肝脏疾病或病状的用途和方法
RU2530651C1 (ru) * 2013-11-06 2014-10-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, обладающее противовоспалительным и антифибротическим действием в легочной ткани при цитостатическом воздействии
KR101538264B1 (ko) * 2014-01-24 2015-07-20 계명대학교 산학협력단 티오리다진과 트레일을 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물
WO2015184794A1 (en) * 2014-06-02 2015-12-10 Chi-Ying Huang Method for treating drug resistant cancer
CN105125571B (zh) * 2015-07-17 2018-11-06 四川大学 Prmt1抑制剂在制备治疗可卡因成瘾的药物中的用途
US20210378992A1 (en) * 2018-10-19 2021-12-09 Auransa Inc. Methods for treating a subtype of small cell lung cancer
BR112021012138A2 (pt) 2018-12-20 2021-08-31 Auransa Inc. Análogos de pentamidina e seus usos
CN109793727A (zh) * 2019-03-13 2019-05-24 湖北科技学院 一种有效抗恶性肿瘤的药物组合物及其应用
KR102562739B1 (ko) * 2020-09-11 2023-08-03 연세대학교 산학협력단 암의 기원 세포의 사멸용 약학적 조성물
CN114588163A (zh) * 2020-12-04 2022-06-07 中国福利会国际和平妇幼保健院 盐酸氯丙嗪在治疗子宫内膜癌中的应用
KR102315103B1 (ko) * 2021-01-21 2021-10-20 주식회사 뉴캔서큐어바이오 티오리다진 및 퍼헥실린을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US2645640A (en) * 1953-07-14 Phenthiazine derivatives
GB1288376A (is) 1968-10-29 1972-09-06
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US5104858A (en) 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
CH681780A5 (en) * 1991-02-25 1993-05-28 Patrinove Anticancer compsns. - consists of a cytotoxic agent with a agent to prevent multi:drug resistance, e.g. in liposome(s)
US5428051A (en) * 1992-10-13 1995-06-27 University Of North Carolina Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5602172A (en) * 1994-05-06 1997-02-11 The University Of North Carolina At Chapel Hill Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor
US5521189A (en) * 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5770585A (en) 1995-05-08 1998-06-23 Kaufman; Robert J. Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5723495A (en) * 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
WO1998000018A1 (en) * 1996-07-03 1998-01-08 Prm Pharmaceuticals, Inc. Berberine alkaloids as a treatment for chronic, protozoally-induced diarrhea
US6008247A (en) * 1998-02-27 1999-12-28 The University Of North Carolina At Chapel Hill 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents
EP1080068A1 (en) 1998-03-12 2001-03-07 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
CA2340912C (en) * 1998-08-20 2008-11-18 University Of North Carolina At Chapel Hill Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof
CA2344445A1 (en) * 1998-09-17 2000-03-23 The University Of North Carolina At Chapel Hill Antifungal activity of dicationic molecules
JP3679943B2 (ja) * 1999-03-02 2005-08-03 大日本印刷株式会社 パターン形成体の製造方法
DK1231910T3 (da) 1999-11-16 2009-08-31 Oncozyme Pharma Inc Pentamidin til behandling af cancer
US6777433B2 (en) * 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
EP1284260A4 (en) * 2000-05-22 2004-03-31 Takeda Chemical Industries Ltd TYROSIN PHOSPHATASE INHIBITORS
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6642221B1 (en) * 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20030161893A1 (en) * 2001-09-07 2003-08-28 Taolin Yi PTPase inhibitors and methods of using the same
JP2005536509A (ja) * 2002-07-11 2005-12-02 コンビナトアールエックス インコーポレーティッド 新生物の治療のための薬物の組み合わせ
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
AU2004273910A1 (en) * 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases

Also Published As

Publication number Publication date
US20050192274A1 (en) 2005-09-01
KR20030048460A (ko) 2003-06-19
AU2002246636B2 (en) 2005-12-01
DE60117615D1 (de) 2006-04-27
AR035500A1 (es) 2004-06-02
NO20032036L (no) 2003-07-04
KR100720205B1 (ko) 2007-05-21
CN1484525A (zh) 2004-03-24
AU2002246636B8 (en) 2006-01-19
SK5452003A3 (en) 2004-07-07
ES2258566T3 (es) 2006-09-01
PL362690A1 (en) 2004-11-02
US20030166642A1 (en) 2003-09-04
HRP20030460A2 (en) 2005-04-30
PT1339399E (pt) 2006-07-31
US20070099906A1 (en) 2007-05-03
NZ525773A (en) 2005-04-29
EP1339399B1 (en) 2006-03-01
EP1339399A2 (en) 2003-09-03
CA2436799C (en) 2007-12-18
EE200300212A (et) 2003-08-15
HUP0400529A2 (hu) 2004-06-28
HUP0400529A3 (en) 2006-02-28
WO2002058684A3 (en) 2003-04-17
BR0115166A (pt) 2003-12-30
TWI259077B (en) 2006-08-01
DK1339399T3 (da) 2006-06-19
RU2286769C2 (ru) 2006-11-10
US6569853B1 (en) 2003-05-27
US7148216B2 (en) 2006-12-12
ATE318590T1 (de) 2006-03-15
IS6806A (is) 2003-05-05
JP2004517915A (ja) 2004-06-17
IL155795A0 (en) 2003-12-23
DE60117615T2 (de) 2006-11-09
US6846816B2 (en) 2005-01-25
NO20032036D0 (no) 2003-05-06
WO2002058684A2 (en) 2002-08-01
BG107831A (bg) 2004-02-27
CY1105501T1 (el) 2010-04-28
CA2436799A1 (en) 2002-08-01
MXPA03003960A (es) 2004-09-10

Similar Documents

Publication Publication Date Title
IS6806A (is) Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum
DK1459750T3 (da) (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
EP1363625A4 (en) COMBINATIONS OF DRUGS (eg, BENZIMIDAZOLE AND PENTAMIDINE) IN THE TREATMENT OF NEOPLASTIC DISORDERS
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
ITRM20020264A1 (it) Articolo assorbente e procedimento per la sua fabbricazione.
IS5720A (is) Latar gegn peptídýli af VLA-4 skilyrtri frumutengingu gagnlegir til meðhöndlunar á bólguvaldandi-, sjálfónæmis, og öndunarsjúkdómum
ITFI20000154A0 (it) Convogliatore radioelettrico asimmetrico terapeutico.
DK1282719T3 (da) Fremgangsmåde til fremstilling af dihydroxyestere og derivater deraf
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
BR8103417Y1 (pt) aparelho para descascar.
IS7003A (is) Arómatisk súlfonhýdroxýamöt og notkun þeirra til tálmunar próteasa
DK1355936T3 (da) Polymerkonjugater af neublastin og fremgangsmåder til anvendelse af samme
DK1041985T3 (da) Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
IS6707A (is) Efnablanda til forvarna og meðhöndlunar á krabbameini
DK1263719T3 (da) N-deacetylthiocolchin-derivater og farmaceutiske sammensætninger indeholdende disse.
IS6098A (is) Ósantant til meðhöndlunar á skaptruflunum
DK1500395T3 (da) Reboxetin til behandling af fibromyalgi og andre somatoforme lidelser
IS6619A (is) S-metýl-díhýdró-siprasídón til meðhöndlunar á geðrænum kvillum og augnkvillum
NO20034785D0 (no) Farmasöytiske kombinasjoner basert på pyridoindolon-derivater og anticancermidler
ITMI20021870A1 (it) Procedimento e dispositivo per fabbricare nastrini di foglia.
NO20040935L (no) Plaster for behandling av dysfunksjoner og forstyrrelser i negler.